Therapeutic | Iratumumab |
Target | TNFRSF8 |
Heavy Chain | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWSWIRQPPGKGLEWIGDINHGGGTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCASLTAYWGQGSLVTVSS |
Light Chain | DIQMTQSPTSLSASVGDRVTITCRASQGISSWLTWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPITFGQGTRLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | Medarex UltiMAb Mouse |
INN Year Proposed | 2005 |
INN Year Recommended | 2006 |
Companies Involved | Medarex |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Hodgkin's disease, Lymphoma, Non-Hodgkin's lymphoma |
Notes |